Q-omics provides the consensus-scored RPL36AP21 profile across patient tissues and cancer cell-line models. RPL36AP21 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPL36AP21 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, RPL36AP21 RNA expression shows 5,594 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, BRCA, and STAD as cancer lineages where RPL36AP21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL36AP21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL36AP21 survival associations across molecular data types. RPL36AP21 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL36AP21 RNA expression–survival associations across cancer types. High RPL36AP21 expression shows unfavorable associations in MESO, but favorable associations in KIRC, SKCM, THCA, COAD and CHOL. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify MESO as the clearest survival context for RPL36AP21 RNA expression.
This table summarizes RPL36AP21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL36AP21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL36AP21 shows lower tumor expression in BRCA and STAD and higher tumor expression in LIHC, PRAD and KIRC. The BRCA box plot shows higher RPL36AP21 RNA expression in normal versus tumor tissue (log2 FC = −0.118, t-test p = .004).
This table shows molecular features associated with RPL36AP21 in patient tissues and cancer cell lines. In patient samples, RPL36AP21 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
